For example, SGLT-2 inhibitors, indicated for type 2 diabetes, chronic kidney disease, and heart failure, have also shown potential applications in reducing contrast-induced acute kidney injury rates in patients with acute coronary syndromes undergoing PCI [149]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.